Imagine trying to see a tiny leak in a city's water pipes using a satellite; you'd see the neighborhood but not the leak. This technology acts like a super-zoom lens for the brain, using sound waves to see the smallest blood vessels without surgery. It lets doctors watch how blood flows in real-time to spot brain diseases much earlier than current tools allow.
Current brain imaging is limited to millimetric resolution, making it impossible to see the smallest blood vessels where many diseases start. This leads to late diagnosis and difficulty in testing the efficacy of neurovascular drugs.
Two fULM scanners (one preclinical and one clinical) and neurocomputational analysis methods for microscopic brain imaging.
If you are an ultrasound equipment manufacturer dealing with the limitation of millimetric resolution in brain scans — this project developed fULM technology that increases spatial resolution by at least two orders of magnitude. This allows for the creation of a new class of high-precision neuroimaging scanners.
If you are a drug developer dealing with the difficulty of measuring drug efficacy in small brain vessels — this project developed a way to monitor the whole brain vasculature at a microscopic level. This enables precise tracking of how a drug affects blood flow dynamics in preclinical models.
If you are a neurology clinic dealing with the inability to capture blood flow dynamics in small vessel diseases — this project developed a non-invasive scanning method for early clinical diagnosis. This provides a tool to detect abnormalities before large-scale symptoms appear.
Based on available project data, there is no information regarding the cost or pricing of the fULM scanners.
The project involves building two unique scanners (preclinical and clinical), suggesting a path toward industrial scaling, though specific manufacturing plans are not detailed.
Based on available project data, the IP and licensing terms are not specified; the project is coordinated by the Institut National de la Santé et de la Recherche Médicale.
The project period runs from 2022-10-01 to 2027-09-30, including a planned First-In-Human study.
The technology is designed to be non-invasive and transcranial, meaning it could potentially integrate into existing radiology or neurology departments as a specialized scanner.
The consortium consists of 6 partners across 4 countries (CH, FR, IT, NL). It is heavily research-oriented, with 2 universities and 2 research institutes, but includes 1 industry partner (17% ratio), indicating a bridge between academic discovery and commercial application.
Contact the Institut National de la Santé et de la Recherche Médicale (INSERM) in France.
Contact us to explore licensing opportunities for fULM technology.
